Skeletal Disease Research and Drug Development | Charles River

skeletal disease 

 
 

New therapies to promote bone healing or treat osteoporosis, arthritis, and other skeletal diseases require a comprehensive preclinical assessment of bone and cartilage. Bone end points can be incorporated into toxicology programs to fully evaluate test articles that have an intended effect on bone or to determine effects of test articles that have secondary, indirect, or adverse effects.

Charles River offers services in the area of bone/skeletal research that combine established discovery, preclinical, and clinical program development expertise with a host of novel bone research technologies that provide highly specialized evaluations of bone disease and bone quality. Our scientists can assess the effect of a drug in vivo or ex vivo on bone at toxicological and pharmacological doses and facilitate the interpretation of study findings to help you better design clinical trials.

Services

Discover the full range of Charles River Products and Services

For more information please call:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jul 01 Charles River Announces RMS Succes...
Jun 01 Contract Pharma: CRO Industry Upda...
Jul 06-Jul 10 Perth, Australia The 2009 Australian Society for Microbiology (ASM) A...
Aug 18-Aug 21 Charleston, SC Charles River’s Annual LAL Workshop
view all
Quality Assurance Inspector Canada - QC -...
Principal Investigator I Tacoma, WA
Sr. Quality Assurance Auditor Frederick, ...
Global Loss Control Specialist, Finance 

Charles River Laboratories, Inc.